Keywords: kamada, completes, ph, iii, trial, aat, therapy
Kamada completes Ph III trial of AAT therapy
Article | 03 November 2008
Kamada, an Israeli biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, has completed the final ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
